Hazardous substances: Medtech firms seeks for continued exemptions under RoHS
This article was originally published in Clinica
Full application of the EU Directive on the Restriction of Hazardous Substances (RoHS) would lead to a significant increase in the costs of some products manufactured by the medical device industry. This would influence healthcare budgets unfavourably. That is the warning made by a group of EU medical device industry associations in a joint statement.